Fortress Biotech, Inc. (FBIO)

Fortress Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	152.19	79.38	57.26	80.93	178.27	305.74
Cash & Short-Term Investments	152.19	79.38	57.26	80.93	178.27	305.74
Cash Growth	76.51%	38.63%	-29.24%	-54.60%	-41.69%	31.02%
Accounts Receivable	47.39	29.78	10.23	15.22	28.21	23.11
Other Receivables	0.05	0.16	0.17	0.17	0.14	0.68
Receivables	47.44	29.94	10.4	15.39	28.35	23.79
Inventory	7.77	9.62	14.43	10.21	14.16	9.86
Prepaid Expenses	2.96	4.9	7.11	10.5	9.66	7.07
Other Current Assets	-	-	1.17	-	-	-
Total Current Assets	210.36	123.84	90.37	117.02	230.43	346.46
Property, Plant & Equipment	13.35	14.82	17.12	23.5	33.01	34.07
Long-Term Investments	29.45	17.66	2.59	-	-	-
Other Intangible Assets	24.54	27.61	31.86	20.29	27.2	12.55
Other Long-Term Assets	2.51	1.62	2.28	6.72	3.66	3.42
Total Assets	280.22	185.55	144.22	167.53	294.3	396.5

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	56.63	14.24	31.64	34.81	57.24	47.43
Accrued Expenses	-	30.71	30.74	34.68	36.51	39.99
Short-Term Debt	-	-	-	3.93	5	0.81
Current Portion of Long-Term Debt	7.5	-	0.63	3	7.24	4.51
Current Portion of Leases	2.51	2.13	2.62	2.52	2.45	2.1
Current Income Taxes Payable	5.12	0.36	0.93	0.84	0.72	0.35
Current Unearned Revenue	-	-	-	-	-	2.61
Other Current Liabilities	-	2.31	4.84	5.13	18.55	3.24
Total Current Liabilities	71.76	49.74	71.4	84.91	127.72	101.04
Long-Term Debt	18.08	52.42	57.96	60.86	93.14	46.56
Long-Term Leases	10.86	12.67	14.75	18.28	21.57	20.99
Other Long-Term Liabilities	2.5	8.53	1.76	1.89	1.85	2.03
Total Liabilities	103.19	123.37	145.87	165.94	244.28	170.63

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.03	0.03	0.03	0.02	0.01	0.1
Additional Paid-In Capital	789.95	783.89	763.57	717.4	675.94	656.03
Retained Earnings	-629.99	-734.05	-740.87	-694.87	-634.23	-547.46
Total Common Equity	159.99	49.87	22.73	22.54	41.72	108.67
Minority Interest	17.02	12.31	-24.38	-20.96	8.3	117.2
Shareholders' Equity	177.02	62.18	-1.64	1.59	50.03	225.88
Total Liabilities & Equity	280.22	185.55	144.22	167.53	294.3	396.5

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	38.95	67.22	75.96	88.59	129.4	74.98
Net Cash (Debt)	113.24	12.17	-18.7	-7.67	48.87	230.77
Net Cash Growth	531.72%	-	-	-	-78.82%	59.95%
Net Cash Per Share	3.30	0.44	-0.90	-0.95	8.25	42.37
Filing Date Shares Outstanding	33.74	32.2	29.53	19.23	8.65	6.97
Total Common Shares Outstanding	33.49	31.36	27.91	15.09	7.37	6.76
Working Capital	138.6	74.1	18.97	32.11	102.72	245.42
Book Value Per Share	4.78	1.59	0.81	1.49	5.66	16.07
Tangible Book Value	135.45	22.27	-9.13	2.25	14.52	96.12
Tangible Book Value Per Share	4.04	0.71	-0.33	0.15	1.97	14.21
Buildings	-	0.58	0.58	0.58	0.58	0.58
Machinery	-	1.61	1.61	1.61	10.76	8.68
Construction In Progress	-	-	-	0.03	0.95	2.03
Leasehold Improvements	-	3.29	11	13.18	13.18	13.18

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 13, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 15, 2026

Data Sources Report a data error